Lori L Altshuler1, Catherine A Sugar1, Susan L McElroy1, Brian Calimlim1, Michael Gitlin1, Paul E Keck1, Ana Aquino-Elias1, Brian E Martens1, E Grace Fischer1, Teri L English1, Janine Roach1, Trisha Suppes1. 1. From the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles; the Jane and Terry Semel Institute of Neuroscience and Human Behavior, University of California, Los Angeles; the Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles; the Department of Biostatistics, School of Public Health, University of California, Los Angeles; the Lindner Center of HOPE, Mason, Ohio; the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati; the Department of Psychiatry and Biobehavioral Sciences, Stanford University School of Medicine, Stanford, Calif.; the VA Palo Alto Health Care System, Palo Alto, Calif.; and the Department of Psychiatry, Olive View-UCLA Medical Center, Sylmar, Calif.
Abstract
OBJECTIVE: The authors compared medication-induced mood switch risk (primary outcome), as well as treatment response and side effects (secondary outcomes) with three acute-phase treatments for bipolar II depression. METHOD: In a 16-week, double-blind, multisite comparison study, 142 participants with bipolar II depression were randomly assigned to receive lithium monotherapy (N=49), sertraline monotherapy (N=45), or combination treatment with lithium and sertraline (N=48). At each visit, mood was assessed using standardized rating scales. Rates of switch were compared, as were rates of treatment response and the presence and severity of treatment-emergent side effects. RESULTS:Twenty participants (14%) experienced a switch during the study period (hypomania, N=17; severe hypomania, N=3). Switch rates did not differ among the three treatment groups, even after accounting for dropout. No patient had a manic switch or was hospitalized for a switch. Most switches occurred within the first 5 weeks of treatment. The treatment response rate for the overall sample was 62.7% (N=89), without significant differences between groups after accounting for dropout. The lithium/sertraline combination group had a significantly higher overall dropout rate than the monotherapy groups but did not have an accelerated time to response. CONCLUSIONS:Lithium monotherapy, sertraline monotherapy, and lithium/sertraline combination therapy were associated with similar switch and treatment response rates in participants with bipolar II depression. The dropout rate was higher in the lithium/sertraline combination treatment group, without any treatment acceleration advantage.
RCT Entities:
OBJECTIVE: The authors compared medication-induced mood switch risk (primary outcome), as well as treatment response and side effects (secondary outcomes) with three acute-phase treatments for bipolar II depression. METHOD: In a 16-week, double-blind, multisite comparison study, 142 participants with bipolar II depression were randomly assigned to receive lithium monotherapy (N=49), sertraline monotherapy (N=45), or combination treatment with lithium and sertraline (N=48). At each visit, mood was assessed using standardized rating scales. Rates of switch were compared, as were rates of treatment response and the presence and severity of treatment-emergent side effects. RESULTS: Twenty participants (14%) experienced a switch during the study period (hypomania, N=17; severe hypomania, N=3). Switch rates did not differ among the three treatment groups, even after accounting for dropout. No patient had a manic switch or was hospitalized for a switch. Most switches occurred within the first 5 weeks of treatment. The treatment response rate for the overall sample was 62.7% (N=89), without significant differences between groups after accounting for dropout. The lithium/sertraline combination group had a significantly higher overall dropout rate than the monotherapy groups but did not have an accelerated time to response. CONCLUSIONS:Lithium monotherapy, sertraline monotherapy, and lithium/sertraline combination therapy were associated with similar switch and treatment response rates in participants with bipolar II depression. The dropout rate was higher in the lithium/sertraline combination treatment group, without any treatment acceleration advantage.
Entities:
Keywords:
Antidepressants; Bipolar Depression; Bipolar II Disorder; Clinical Drug Studies; Drug Side Effects-Other; Lithium
Authors: Nancy Byatt; Lucille Cox; Tiffany A Moore Simas; Nisha Kini; Kathleen Biebel; Padma Sankaran; Holly A Swartz; Linda Weinreb Journal: Arch Womens Ment Health Date: 2018-03-13 Impact factor: 3.633
Authors: Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk Journal: Bipolar Disord Date: 2018-03-14 Impact factor: 6.744
Authors: Jin Hong Park; Nicolas A Nuñez; Manuel Gardea-Resendez; Danielle J Gerberi; Scott Breitinger; Marin Veldic; Mark A Frye; Balwinder Singh Journal: Psychopharmacol Bull Date: 2022-05-31
Authors: Victoria E Cosgrove; Santiago Allende; Iola Gwizdowski; E Grace Fischer; Michael Ostacher; Trisha Suppes Journal: Int J Bipolar Disord Date: 2022-03-02